NCT03179631Phase 3Completed

Long-Term Outcomes of Ataluren in Duchenne Muscular Dystrophy

Study sponsor: PTC Therapeutics

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2022-03-05Actual
Enrollment · participants360Actual
Source updated2026-03-10Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 1 field changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Slope of Change in 6-Minute Walk Distance (6MWD) Over 72 Weeks. After: Measure: DB Period: Change From Baseline in 6-Minute Walk Distance (6MWD) at Week 72 - Modified Intention-to-treat (mITT) Population Measure: DB Period: Change From Baseline in 6MWD at Week 72 - Intent-to-Treat (ITT) Population Measure: DB Period: Average Rate of Change From Baseline in 6MWD at Week 72 - mITT Population Measure: DB Period: Average Rate of Change From Baseline in 6MWD at Week 72 - ITT Population.

Check registry source

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview